Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6886 to 6900 of 7680 results

  1. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  2. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued [GID-TA10811]

    Technology appraisal guidance
    Discontinued

  3. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

    NICE guideline
    Discontinued

  4. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development [GID-TA10489] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

    Technology appraisal guidance
    Discontinued

  6. Workplace health - older employees

    Discontinued [GID-PHG59]

    NICE guideline
    Discontinued

  7. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

    Medical technologies guidance
    Discontinued

  8. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  10. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

    Technology appraisal guidance
    Discontinued

  11. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued [GID-TAG439]

    Technology appraisal guidance
    Discontinued

  12. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  13. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued [GID-TA10177]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

    Technology appraisal guidance
    Discontinued

  15. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued [GID-TAG404]

    Technology appraisal guidance
    Discontinued